ClinicalTrials.gg
CompletedNCT03327220Updated May 21, 2021Results posted

Treatment With Iovera° for Total Knee Arthroplasty (TKA) Post-Operative Pain

An interventional study of iovera° in Total Knee Arthroplasty, sponsored by Pacira Pharmaceuticals, Inc. Completed at 1 site in United States. Open to participants aged 22 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-21.

Sponsored by Pacira Pharmaceuticals, Inc · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
22 Years to 79 Years
Sex
All
01

Study summary

This study is designed to investigate whether iovera° treatment prior to TKA decreases cumulative participant opioid use over the course of 6 weeks following TKA while maintaining similar levels of pain relief. The study will also investigate whether there is a relationship between participants treated with iovera° and participant reported pain and function as measured by knee injury and osteoarthritis outcomes score (KOOS JR), numeric rating scale (NRS) for pain; use of hospital services post-TKA and improved physical rehabilitation as measured by range of motion.

02

Conditions studied

  • Total Knee Arthroplasty
03

In context

Lead sponsor

Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.

Of its 27 completed or terminated interventional studies of FDA-regulated products, 17 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 22 to 79 years of age
  2. Scheduled to undergo primary unilateral TKA under spinal anesthesia for primary diagnosis of osteoarthritis
  3. Participant is a class I-III on the American Society of Anesthesiology (ASA) Physical Classification System
  4. Anticipation of discharge to home after inpatient acute post-op phase based on age, co-morbidities, home environment, and social support are in favor of discharge to home in the opinion of the Investigator.
  5. Participant is willing and able to give written .
  6. Participant is fluent in verbal and written English.
  7. Participant is willing and able to comply with study instructions and commit to all follow-up visits for the duration of the study.
  8. Participant is in good general health and free of any systemic disease state or physical condition that might impair evaluation or which in the Investigator's opinion, exposes the participant to an unacceptable risk by study participation.

Exclusion criteria

Exclusion Criteria:

  1. Chronic opioid use (defined as daily or almost daily use of opioids for >3 months).
  2. Concurrent painful physical condition, surgery, or musculoskeletal disease that requires analgesic treatment during study follow-up that is not strictly related to the target knee being treated with iovera°, which have the potential to confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent or planned contralateral TKA, concurrent foot, neck, spine, hip, or other musculoskeletal disease, arthritis, or planned surgery, etc.).
  3. Greater than 15° malalignment (varus or valgus) on pre-operative radiograph.
  4. Previous Myoscience treatment.
  5. Previous Partial or Total Knee Arthroplasty. Partial or Total Knee Arthroplasty of the contralateral knee is permitted if surgery was completed at least nine (9) months prior to Screening.
  6. ≥ 40
  7. Prior surgery in the treatment areas that may alter the anatomy of the infrapatellar branch of the saphenous nerve (ISN) or the anterior femoral cutaneous nerve (AFCN) or result in scar tissue in the treatment area.
  8. Any clotting disorder and/or use of an anticoagulant (e.g. warfarin, clopidogrel, etc.) within seven (7) days prior to administration of the device. Low dose aspirin (81mg or less daily) for cardiac prophylaxis allowed.
  9. Any local skin condition at the treatment sites that in the Investigator's opinion would adversely affect treatment or outcomes.
  10. Open and/or infected wound in the treatment areas.
  11. Allergy to lidocaine.
  12. History of cryoglobulinemia
  13. History of paroxysmal cold hemoglobinuria.
  14. History of cold urticaria.
  15. History of Raynaud's disease.
  16. History of opioid or alcohol abuse.
  17. Participant is pregnant or planning to become pregnant while enrolled in the study.
  18. Current enrollment in any drug or device study or participation within 30 days prior to screening.
  19. Currently being treated for related knee injury under worker's compensation claim or equivalent (i.e. legal case).
  20. Any chronic medical condition that in the Investigator's opinion would prevent adequate participation.
  21. Any chronic medication use (prescription, over-the-counter, etc.) that in the Investigator's opinion would affect study participation or participant safety.
  22. For any reason, in the opinion of the Investigator, the participant may not be a suitable candidate for study participation (i.e., history of noncompliance, drug dependency, etc.).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    iovera° Device Treatment Group

    Iovera° device presurgical cryoneurolysis treatment, 5 (+/- 2) days prior to TKA. Additionally, all participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.

    Device: iovera°

  • No intervention
    Standard of Care Treatment Group

    All participants received treatment as per all the standard pre-, peri-, and post-operative surgical protocols.

Interventions

  • Deviceiovera°

    The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.

06

What researchers measure

Primary outcomes

  1. Cumulative Opioid Consumption

    The cumulative consumption of opioids was determined from the time of Total Knee Arthroplasty (TKA) surgery to 6 weeks post-TKA surgery. Opioid consumption was converted to morphine milligram equivalents (MME) and participant consumption was verified by pill count at follow-up visits. The cumulative morphine equivalent was divided by the number of days to provide the total daily morphine equivalent (TME) for the participant,

    Time frame: From the time of TKA surgery to 6 weeks post-TKA surgery

Secondary outcomes

  1. Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA

    The KOOS JR. was a participant completed questionnaire that consists of 7 questions from 3 subscales: stiffness (1 question), pain (4 questions), and function in daily living (2 questions). Standardized answer options are given (5 Likert boxes) and each question was assigned a score from none (0) to extreme (4). A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) was calculated. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in KOOS JR. scores through 6 weeks post-TKA, is the AUC of Change in KOOS JR. scores from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the KOOS JR. score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

    Time frame: Baseline to 6 weeks post-TKA surgery

  2. AUC/Time for Change From Baseline in Numeric Rating Scale (NRS) for Pain Through 6 Weeks Post-TKA

    NRS was an 11-point scale for self-reporting of pain intensity by participants. Scores range from 0 to 10, where 0 points equals "no pain" and 10 points equals the "worst pain imaginable". A positive change represented improvement (or reduction) in pain intensity. AUC/time based on Changes from Baseline in NRS Pain score through 6 weeks post-TKA, is the AUC of Change in NRS for Pain score from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the NRS for Pain score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

    Time frame: Baseline to 6 weeks post-TKA surgery

  3. AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA

    The time required by the participants to raise from sitting, walk 10 feet, turn around, walk back and sit back down was measured in seconds. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in the TUG test through 6 weeks post-TKA, is the AUC of Change in TUG test from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the TUG test at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

    Time frame: Baseline to 6 weeks post-TKA surgery

07

Results

Posted May 21, 2021
Limitations and caveats
This study was acquired from another sponsor. Results for the Primary Outcome Measure, Cumulative Opioid Consumption, are reported for the Time Frame (From the time of TKA surgery to 6 weeks post-TKA surgery) because the results for the Time Frame (From the time of hospital discharge to 6 weeks post-TKA surgery) are not available.

Participant flow

Participant flow — Overall Study
MilestoneIovera° Device Treatment GroupStandard of Care Treatment Group
Started6262
Safety population: received study treatment5960
Completed5758
Not completed54
Withdrew: Adverse event (ae)/serious adverse event (sae)12
Withdrew: Investigator decision20
Withdrew: Missed visit 6 (week 6 visit)01
Withdrew: Fungal infection10
Withdrew: Discharged to rehabilitation01
Withdrew: Missing10

Outcome measures

PrimaryCumulative Opioid Consumption

The cumulative consumption of opioids was determined from the time of Total Knee Arthroplasty (TKA) surgery to 6 weeks post-TKA surgery. Opioid consumption was converted to morphine milligram equivalents (MME) and participant consumption was verified by pill count at follow-up visits. The cumulative morphine equivalent was divided by the number of days to provide the total daily morphine equivalent (TME) for the participant,

Time frame:
From the time of TKA surgery to 6 weeks post-TKA surgery
Reported as:
Mean · TME
Cumulative Opioid Consumption
TMEIovera° Device Treatment GroupStandard of Care Treatment Group
Cumulative Opioid Consumption4.8 ± 0.76.1 ± 0.7
Statistical analysis
  • Iovera° Device Treatment Group vs Standard of Care Treatment Group · t-test, 1 sided · p = 0.0841 (p-value was calculated from a one-sided, two-sample t-test.) · Difference in means: 1.3 · 95% CI -0.6 to 3.2
SecondaryArea Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA

The KOOS JR. was a participant completed questionnaire that consists of 7 questions from 3 subscales: stiffness (1 question), pain (4 questions), and function in daily living (2 questions). Standardized answer options are given (5 Likert boxes) and each question was assigned a score from none (0) to extreme (4). A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) was calculated. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in KOOS JR. scores through 6 weeks post-TKA, is the AUC of Change in KOOS JR. scores from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the KOOS JR. score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

Time frame:
Baseline to 6 weeks post-TKA surgery
Reported as:
Mean · score on a scale/days
Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA
score on a scale/daysIovera° Device Treatment GroupStandard of Care Treatment Group
Area Under the Curve (AUC)/Time for Change From Baseline in Knee Injury and Osteoarthritis Outcomes Score (KOOS JR.) Overall Score Through 6 Weeks Post-TKA10.3 ± 1.68.4 ± 1.4
Statistical analysis
  • Iovera° Device Treatment Group vs Standard of Care Treatment Group · t-test, 1 sided · p = <0.0001 (p-value was calculated from a one-sided, two-sample t-test.) · Difference in means: 1.9 · 95% CI -2.3 to 6.1
SecondaryAUC/Time for Change From Baseline in Numeric Rating Scale (NRS) for Pain Through 6 Weeks Post-TKA

NRS was an 11-point scale for self-reporting of pain intensity by participants. Scores range from 0 to 10, where 0 points equals "no pain" and 10 points equals the "worst pain imaginable". A positive change represented improvement (or reduction) in pain intensity. AUC/time based on Changes from Baseline in NRS Pain score through 6 weeks post-TKA, is the AUC of Change in NRS for Pain score from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the NRS for Pain score at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

Time frame:
Baseline to 6 weeks post-TKA surgery
Reported as:
Mean · score on a scale/days
AUC/Time for Change From Baseline in Numeric Rating Scale (NRS) for Pain Through 6 Weeks Post-TKA
score on a scale/daysIovera° Device Treatment GroupStandard of Care Treatment Group
Pain in The Past 7 Days2.2 ± 2.11.7 ± 1.9
Pain Right Now1.9 ± 2.71.5 ± 2.3
Statistical analysis
  • Iovera° Device Treatment Group vs Standard of Care Treatment Group · t-test, 1 sided · p = 0.0946 (p-value was calculated from a one-sided, two-sample t-test.) · Difference in means: 0.5 · 95% CI -0.2 to 1.2
  • Iovera° Device Treatment Group vs Standard of Care Treatment Group · t-test, 1 sided · p = 0.2204 (p-value was calculated from a one-sided, two-sample t-test,) · Difference in means: 0.4 · 95% CI -0.6 to 1.3
SecondaryAUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA

The time required by the participants to raise from sitting, walk 10 feet, turn around, walk back and sit back down was measured in seconds. A positive change from baseline indicates improvement. AUC/time based on Changes from Baseline in the TUG test through 6 weeks post-TKA, is the AUC of Change in TUG test from the Baseline visit through the 6-week visit divided by the number of days from TKA until the 6-week visit. AUC was calculated using the trapezoidal rule and the changes in the TUG test at the following time points: Baseline (change=0), 72 hours, 2 weeks, and 6 weeks post-TKA.

Time frame:
Baseline to 6 weeks post-TKA surgery
Reported as:
Mean · seconds/days
AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA
seconds/daysIovera° Device Treatment GroupStandard of Care Treatment Group
AUC/Time for Change From Baseline in Timed Get Up and Go (TUG) Tests Through 6 Weeks Post-TKA-1.2 ± 5.5-0.4 ± 11.3
Statistical analysis
  • Iovera° Device Treatment Group vs Standard of Care Treatment Group · t-test, 1 sided · p = 0.3231 (p-value was calculated from a one-sided, two-sample t-test.) · Difference in means: -0.8 · 95% CI -4.0 to 2.5

Adverse events

Collected over From first treatment up to the end of the study (Up to approximately 12 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Iovera° Device Treatment Group0/62 (0%)2/59 (3.4%)4/59 (6.8%)
Standard of Care Treatment Group0/62 (0%)2/60 (3.3%)3/60 (5%)
Most frequent serious events
Most frequent serious events
EventIovera° Device Treatment GroupStandard of Care Treatment Group
Bilateral Pulmonary EmboliVascular disorders1/590/60
R/O Popliteal Arterial AneurysmVascular disorders1/590/60
Neuropsychotic/seizuresPsychiatric disorders1/591/60
AnaphylaxisSkin and subcutaneous tissue disorders1/591/60
Most frequent other events
Most frequent other events
EventIovera° Device Treatment GroupStandard of Care Treatment Group
R/O Deep vein thrombosisVascular disorders4/593/60

Baseline characteristics

Intent-to-Treat (ITT) population included all participants who were randomized into the study.

Age, Continuous
Age, Continuous(years)Iovera° Device Treatment GroupStandard of Care Treatment GroupTotal
Mean65.5 ± 8.266.2 ± 7.165.9 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Iovera° Device Treatment GroupStandard of Care Treatment GroupTotal
Female313667
Male312657
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Iovera° Device Treatment GroupStandard of Care Treatment GroupTotal
Hispanic or Latino000
Not Hispanic or Latino6262124
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Iovera° Device Treatment GroupStandard of Care Treatment GroupTotal
Asian101
Black or African American101525
White524799
08

Study locations

1 site
  • Campbell Clinic
    Germantown, Tennessee 38138, United States
09

References and documents

Publications

  • Mihalko WM, Kerkhof AL, Ford MC, Crockarell JR Jr, Harkess JW, Guyton JL. Cryoneurolysis before Total Knee Arthroplasty in Patients With Severe Osteoarthritis for Reduction of Postoperative Pain and Opioid Use in a Single-Center Randomized Controlled Trial. J Arthroplasty. 2021 May;36(5):1590-1598. doi: 10.1016/j.arth.2020.11.013. Epub 2020 Nov 14. PubMed 33279353 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Mar 2019, 16 months.

Results were first posted in May 2021, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Oct 31, 2017
StartActual
Nov 6, 2017
Primary completionActual
Mar 27, 2019
CompletionActual
Mar 27, 2019
Results first posted
May 21, 2021
Last update
May 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03327220
Responsible party
Sponsor
First posted
Oct 31, 2017
Start date
Nov 6, 2017
Primary completion
Mar 27, 2019
Completion
Mar 27, 2019
Results posted
May 21, 2021
Last update
May 21, 2021

Study contacts

William Mihalko, MD, PhD
principal investigator · UTHSC - COM - Orthopaedic Surgery & Biomedical Engineering

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion